Gene therapy clinical trials worldwide to 2007 - an update

被引:421
作者
Edelstein, Michael L.
Abedi, Mohammad R.
Wixon, Jo [1 ]
机构
[1] John Wiley & Sons Ltd, Chichester PO19 8SQ, W Sussex, England
[2] Orebro Univ Hosp, Dept Transfus Med, S-70185 Orebro, Sweden
[3] Hemel Hempstead Hosp, Hemel Hempstead HP2 4AD, England
关键词
SEVERE COMBINED IMMUNODEFICIENCY; SERIOUS ADVERSE EVENT; EUROPEAN-SOCIETY; VECTORS;
D O I
10.1002/jgm.1100
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
To date, over 1340 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide. In 1997 we set up a database to bring together global information on gene therapy clinical trials as comprehensively as possible. The data are compiled and regularly updated from official agency sources, published literature, conference presentations and posters and from information kindly provided by investigators or trial sponsors themselves. This review updates our descriptive overview of the data in 2004 [1], presenting our analysis of the clinical trials that, to the best of our knowledge, have been or are being performed worldwide. As of July 30 2007, we have stored entries on 1309 trials in 28 countries. We have analyzed the geographical distribution of trials, the disease indications (or the proportions to which different vector types other reasons) for trials, and which genes have been transferred. Details of the analyses are used, presented, and our interactive, searchable database can be found on The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide website at: http://www.wiley.co.uk/genmed/clinical. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:833 / 842
页数:10
相关论文
共 31 条
[21]   LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 [J].
Hacein-Bey-Abina, S ;
Von Kalle, C ;
Schmidt, M ;
McCcormack, MP ;
Wulffraat, N ;
Leboulch, P ;
Lim, A ;
Osborne, CS ;
Pawliuk, R ;
Morillon, E ;
Sorensen, R ;
Forster, A ;
Fraser, P ;
Cohen, JI ;
de Saint Basile, G ;
Alexander, I ;
Wintergerst, U ;
Frebourg, T ;
Aurias, A ;
Stoppa-Lyonnet, D ;
Romana, S ;
Radford-Weiss, I ;
Gross, F ;
Valensi, F ;
Delabesse, E ;
Macintyre, E ;
Sigaux, F ;
Soulier, J ;
Leiva, LE ;
Wissler, M ;
Prinz, C ;
Rabbitts, TH ;
Le Deist, F ;
Fischer, A ;
Cavazzana-Calvo, M .
SCIENCE, 2003, 302 (5644) :415-419
[22]   A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency [J].
Hacein-Bey-Abina, S ;
von Kalle, C ;
Schmidt, M ;
Le Deist, F ;
Wulffraat, N ;
McIntyre, E ;
Radford, I ;
Villeval, JL ;
Fraser, CC ;
Cavazzana-Calvo, M ;
Fischer, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03) :255-256
[23]   Letter to the editors of Nature from the American Society of Gene Therapy (ASGT) and the European Society of Gene Therapy (ESGT) [J].
Kohn, DB ;
Gänsbacher, B .
JOURNAL OF GENE MEDICINE, 2003, 5 (07) :641-641
[24]   Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns [J].
Laufs, S ;
Nagy, KZ ;
Giordano, FA ;
Hotz-Wagenblatt, A ;
Zeller, WJ ;
Fruehauf, S .
MOLECULAR THERAPY, 2004, 10 (05) :874-881
[25]   Cancer regression in patients after transfer of genetically engineered lymphocytes [J].
Morgan, Richard A. ;
Dudley, Mark E. ;
Wunderlich, John R. ;
Hughes, Marybeth S. ;
Yang, James C. ;
Sherry, Richard M. ;
Royal, Richard E. ;
Topalian, Suzanne L. ;
Kammula, Udai S. ;
Restifo, Nicholas P. ;
Zheng, Zhili ;
Nahvi, Azam ;
de Vries, Christiaan R. ;
Rogers-Freezer, Linda J. ;
Mavroukakis, Sharon A. ;
Rosenberg, Steven A. .
SCIENCE, 2006, 314 (5796) :126-129
[26]   Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 [J].
Ott, MG ;
Schmidt, M ;
Schwarzwaelder, K ;
Stein, S ;
Siler, U ;
Koehl, U ;
Glimm, H ;
Kühlcke, K ;
Schilz, A ;
Kunkel, H ;
Naundorf, S ;
Brinkmann, A ;
Deichmann, A ;
Fischer, M ;
Ball, C ;
Pilz, I ;
Dunbar, C ;
Du, Y ;
Jenkins, NA ;
Copeland, NG ;
Lüthi, U ;
Hassan, M ;
Thrasher, AJ ;
Hoelzer, D ;
von Kalle, C ;
Seger, R ;
Grez, M .
NATURE MEDICINE, 2006, 12 (04) :401-409
[27]   Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers [J].
Peng, ZH .
HUMAN GENE THERAPY, 2005, 16 (09) :1016-1027
[28]   Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer [J].
Raper, SE ;
Chirmule, N ;
Lee, FS ;
Wivel, NA ;
Bagg, A ;
Gao, GP ;
Wilson, JM ;
Batshaw, ML .
MOLECULAR GENETICS AND METABOLISM, 2003, 80 (1-2) :148-158
[29]   Induction of the interferon response by siRNA is cell type- and duplex length-dependent [J].
Reynolds, Angela ;
Anderson, Emily M. ;
Vermeulen, Annaleen ;
Fedorov, Yuriy ;
Robinson, Kathryn ;
Leake, Devin ;
Karpilow, Jon ;
Marshall, William S. ;
Khvorova, Anastasia .
RNA, 2006, 12 (06) :988-993
[30]   GENE-TRANSFER INTO HUMANS - IMMUNOTHERAPY OF PATIENTS WITH ADVANCED MELANOMA, USING TUMOR-INFILTRATING LYMPHOCYTES MODIFIED BY RETROVIRAL GENE TRANSDUCTION [J].
ROSENBERG, SA ;
AEBERSOLD, P ;
CORNETTA, K ;
KASID, A ;
MORGAN, RA ;
MOEN, R ;
KARSON, EM ;
LOTZE, MT ;
YANG, JC ;
TOPALIAN, SL ;
MERINO, MJ ;
CULVER, K ;
MILLER, AD ;
BLAESE, RM ;
ANDERSON, WF .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (09) :570-578